Filing Flows › Health Care › Sanofi (SNY)

Sanofi (SNY) earnings and revenue breakdown

Latest: Q3 2026 · 6-K filed Oct 30, 2026 · Sanofi (SNY) Q3 2026 earnings results →

Q3 2026 Revenue up 16% year over year to $14.4B · 21¢ of every $1 of revenue kept as net profit · operating margin 30.1%

Sanofi made $14.4B in Q3 2026 (+16% Y/Y): Sales at constant exchange rates $14.2B, Effect of exchange rates $228M. Operating margin 30.1%, net earnings $3.0B. See where every dollar goes — costs, profit and cash — as a Sankey from the 6-K filed Oct 30, 2026.

Revenue$14.4B

Year over year+16%

Operating margin30.1%

Net earnings$3.0B

Operating cash flow—

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was €14.4B in Q3 2026, up 16% year over year. Sales at constant exchange rates was the largest line at 98% of revenue.

Gross margin was 80.3%, up 1.8 points from a year earlier. Operating profit was €4.3B, a 30.1% margin (up 1.0 points year over year). Of the extra revenue versus a year earlier, 36% reached operating profit, above the 29% margin then. Operating expenses grew 18% against revenue growth of 16%. The fastest-growing cost line was Other operating costs (+26%). Net earnings were €3.0B, up 8% year over year. The effective tax rate was -65.2%.

Quarterly history

Quarter	Form	Filed	Revenue	Y/Y	Op. margin	Net earnings	Op. cash flow
Q3 2026	6-K	Oct 30, 2026	$14.4B	+16%	30.1%	$3.0B	—

Charts

Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.